The Use of Cyproheptadine in Pediatric Feeding Disorders
The Use of Cyproheptadine to Improve Eating Habits in Children With Pediatric Feeding Disorders
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Antonia Rovira, MD
- Phone Number: 3052433166
- Email: acr148@miami.edu
Study Locations
-
-
Florida
-
Miami, Florida, United States, 30345
- University of Miami Department of Pediatric Gastroenterology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Any patient aged 2-6 years of age who presents to Pediatric Gastroenterology Clinic with complaint of "poor weight gain, malnutrition, failure to thrive/weight faltering, picky eating, or feeding issues" who screens positive for a pediatric feeding disorder using the Child eating disorder questionnaire (CEBQ)
- Age Range: 2-6 years
- English or Spanish speaking
Exclusion Criteria:
- Patients who are tube fed
- Patients who are overweight (BMI at 85th%tile or greater)
- Patients who have active symptoms from a diagnosis of a GI disorder (Inflammatory Bowel Disease, Eosinophilic Esophagitis, Gastritis)
- Patients actively undergoing behavioral feeding therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Nutritional Counseling in Combination with Behavioral Counseling
Participants in the group will receive nutritional and behavioral counseling for up to 6 months
|
This includes in person counseling by a provider once in office for up to 15 minutes as well as standardized hand out with basic nutritional guidance on high-calorie foods.
This includes in person counseling by a provider once in office for up to 15 minutes as well as standardized hand out with basic behavioral guidance.
|
|
Experimental: Cyproheptadine
Participants in this group will receive the Cyproheptadine for up to 6 months
|
This includes in person counseling by a provider once in office for up to 15 minutes as well as standardized hand out with basic nutritional guidance on high-calorie foods.
This includes in person counseling by a provider once in office for up to 15 minutes as well as standardized hand out with basic behavioral guidance.
Initiation of Cyproheptadine at 0.25mg/kg once daily by mouth at bedtime and titration up to at most three times daily as per participant's primary gastroenterologist.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Children's Eating Behavior Questionnaire score
Time Frame: Baseline and up to 6 months
|
A composite score will be obtained and scores range from 1-5 with higher scores indicating more behavioral eating.
|
Baseline and up to 6 months
|
|
Number of foods consumed by participants
Time Frame: Baseline and up to 6 months
|
Number of food consumed will be collected.
Number of foods consumed as defined as eaten more than once per month.
|
Baseline and up to 6 months
|
|
Change in Child Food Neophobia score
Time Frame: Baseline and up to 6 months
|
Score of 10-70 with higher score indicating higher neophobia.
|
Baseline and up to 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in weight
Time Frame: Baseline and up to 6 months
|
Weight measured in kilograms
|
Baseline and up to 6 months
|
|
Change in height
Time Frame: Baseline and up to 6 months
|
Height measured in centimeters
|
Baseline and up to 6 months
|
|
Change in BMI
Time Frame: Baseline and up to 6 months
|
BMI measured in kg/m2
|
Baseline and up to 6 months
|
|
Change in BMI percentile
Time Frame: Baseline and up to 6 months
|
BMI measured in percent
|
Baseline and up to 6 months
|
|
Change in BMI Z-score
Time Frame: Baseline and up to 6 months
|
BMI measured in standard deviation units
|
Baseline and up to 6 months
|
|
Number of treatment related adverse events
Time Frame: Up to 6 months
|
Number of treatment related adverse events using the National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) version 5 as per physician discretion.
|
Up to 6 months
|
|
Parent's perception of medication's effects
Time Frame: Up to 6 months
|
Measured by Cyproheptadine Survey given to parents in yes/no format.
Total sum of yes and no answers will be collected.
|
Up to 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Miguel Saps, MD, University of Miami
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Organizing Pneumonia
- Mental Disorders
- Nutrition Disorders
- Immune System Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Bronchial Diseases
- Lung Diseases, Obstructive
- Bronchiolitis Obliterans
- Bronchiolitis
- Bronchitis
- Feeding and Eating Disorders
- Graft vs Host Disease
- Nutritional and Metabolic Diseases
- Avoidant Restrictive Food Intake Disorder
- Bronchiolitis Obliterans Syndrome
- Malnutrition
- Health Care Quality, Access, and Evaluation
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Investigative Techniques
- Epidemiologic Methods
- Hydrocarbons
- Hydrocarbons, Cyclic
- Data Collection
- Health Care Evaluation Mechanisms
- Quality of Health Care
- Public Health
- Environment and Public Health
- Polycyclic Aromatic Hydrocarbons
- Hydrocarbons, Aromatic
- Polycyclic Compounds
- Piperidines
- Psychotherapy
- Behavioral Disciplines and Activities
- Epidemiologic Measurements
- Dibenzocycloheptenes
- Benzocycloheptenes
- Cyproheptadine
- Nutrition Assessment
- Behavior Therapy
Other Study ID Numbers
Other Study ID Numbers
- 20240756
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.